PIM-1 Is Overexpressed at a High Frequency in Circulating Tumor Cells from Metastatic Castration-Resistant Prostate Cancer Patients
PIM-1 is an oncogene involved in cell cycle progression, cell growth, cell survival and therapy resistance, activated in many types of cancer, and is now considered as a very promising target for cancer therapy. We report for the first time that PIM-1 is overexpressed in circulating tumor cells (CTCs) from metastatic castration-resistant prostate cancer patients (mCRPC). We first developed and validated a highly sensitive RT-qPCR assay for quantification of PIM-1 transcripts. We further applied this assay to study PIM-1 expression in EpCAM(+) CTC fraction isolated from 64 peripheral blood samples of 50 mCRPC patients. CTC enumeration in all samples was performed using the FDA-cleared CellSearch® system. PIM-1 overexpression was detected in 24/64 (37.5%) cases, while in 20/24 (83.3%) cases that were positive for PIM-1 expression, at least one CTC/7.5 mL PB was detected in the CellSearch®. Our data indicate that PIM-1 overexpression is observed at high frequency in CTCs from mCRPC patients and this finding, in combination with androgen receptor splice variant 7 (AR-V7) expression in CTCs, suggest its potential role as a very promising target for cancer therapy. We strongly believe that PIM-1 overexpression in EpCAM(+) CTC fraction merits to be further evaluated and validated as a non-invasive circulating tumor biomarker in a large and well-defined patient cohort with mCRPC.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
---|---|
Enthalten in: |
Cancers - 12(2020), 5 vom: 08. Mai |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Markou, Athina [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Revised 28.09.2020 published: Electronic Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.3390/cancers12051188 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM309801656 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM309801656 | ||
003 | DE-627 | ||
005 | 20231225134718.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/cancers12051188 |2 doi | |
028 | 5 | 2 | |a pubmed24n1032.xml |
035 | |a (DE-627)NLM309801656 | ||
035 | |a (NLM)32397108 | ||
035 | |a (PII)E1188 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Markou, Athina |e verfasserin |4 aut | |
245 | 1 | 0 | |a PIM-1 Is Overexpressed at a High Frequency in Circulating Tumor Cells from Metastatic Castration-Resistant Prostate Cancer Patients |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 28.09.2020 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a PIM-1 is an oncogene involved in cell cycle progression, cell growth, cell survival and therapy resistance, activated in many types of cancer, and is now considered as a very promising target for cancer therapy. We report for the first time that PIM-1 is overexpressed in circulating tumor cells (CTCs) from metastatic castration-resistant prostate cancer patients (mCRPC). We first developed and validated a highly sensitive RT-qPCR assay for quantification of PIM-1 transcripts. We further applied this assay to study PIM-1 expression in EpCAM(+) CTC fraction isolated from 64 peripheral blood samples of 50 mCRPC patients. CTC enumeration in all samples was performed using the FDA-cleared CellSearch® system. PIM-1 overexpression was detected in 24/64 (37.5%) cases, while in 20/24 (83.3%) cases that were positive for PIM-1 expression, at least one CTC/7.5 mL PB was detected in the CellSearch®. Our data indicate that PIM-1 overexpression is observed at high frequency in CTCs from mCRPC patients and this finding, in combination with androgen receptor splice variant 7 (AR-V7) expression in CTCs, suggest its potential role as a very promising target for cancer therapy. We strongly believe that PIM-1 overexpression in EpCAM(+) CTC fraction merits to be further evaluated and validated as a non-invasive circulating tumor biomarker in a large and well-defined patient cohort with mCRPC | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a AR-V7 | |
650 | 4 | |a CTCs | |
650 | 4 | |a PIM-1 | |
650 | 4 | |a RT-qPCR | |
650 | 4 | |a liquid biopsy | |
650 | 4 | |a mCRPC | |
700 | 1 | |a Tzanikou, Eleni |e verfasserin |4 aut | |
700 | 1 | |a Strati, Areti |e verfasserin |4 aut | |
700 | 1 | |a Zavridou, Martha |e verfasserin |4 aut | |
700 | 1 | |a Mastoraki, Sophia |e verfasserin |4 aut | |
700 | 1 | |a Bournakis, Evangelos |e verfasserin |4 aut | |
700 | 1 | |a Lianidou, Evi |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Cancers |d 2009 |g 12(2020), 5 vom: 08. Mai |w (DE-627)NLM198667213 |x 2072-6694 |7 nnns |
773 | 1 | 8 | |g volume:12 |g year:2020 |g number:5 |g day:08 |g month:05 |
856 | 4 | 0 | |u http://dx.doi.org/10.3390/cancers12051188 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 12 |j 2020 |e 5 |b 08 |c 05 |